Targeting the Metabolic Pathway of Human Colon Cancer Overcomes Resistance to TRAIL-induced Apoptosis

Overview

Journal Cell Death Discov

Date 2016 Sep 21

PMID 27648301

Citations 14

Authors

Ryan M Carr

Guilin Qiao

Jianzhong Qin

Sundararajan Jayaraman

Bellur S Prabhakar

Ajay V Maker

Affiliations

Soon will be listed here.

Abstract

Colon cancer is a leading cause of cancer-related mortality for which targeted therapy is needed; however, trials using apoptosis-inducing ligand monotherapy to overcome resistance to apoptosis have not shown clinical responses. Since colon cancer cells selectively uptake and rapidly metabolize glucose, a property utilized for clinical staging, we investigated mechanisms to alter glucose metabolism in order to selectively target the cancer cells and to overcome evasion of apoptosis. We demonstrate TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) resistance in the majority of human colon cancers tested and utilize the glucose analog 2-deoxy-d-glucose to sensitize TRAIL-resistant gastrointestinal adenocarcinoma cells, and not normal gastrointestinal epithelial cells, to TRAIL-induced apoptosis through enhanced death receptor 5 expression, downstream modulation of MAPK signaling and subsequent miRNA expression modulation by increasing the expression of miR-494 via MEK activation. Further, established human colon cancer xenografts treated with this strategy experience anti-tumor responses. These findings in colon adenocarcinoma support further investigation of manipulation of cellular energetics to selectively overcome resistance to apoptosis and to impart tumor regressions in established colon cancer tumors.

Citing Articles

Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures.

Tanaka A, Ogawa M, Zhou Y, Namba K, Hendrickson R, Miele M Cell Rep. 2024; 43(2):113810.

PMID: 38377004 PMC: 11288375. DOI: 10.1016/j.celrep.2024.113810.

Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.

El Yousfi Y, Mora-Molina R, Lopez-Rivas A, Yerbes R Cells. 2023; 12(19).

PMID: 37830584 PMC: 10571597. DOI: 10.3390/cells12192370.

Induction of RIPK3/MLKL-mediated necroptosis by Erigeron breviscapus injection exhibits potent antitumor effect.

Guo X, Li R, Cui J, Hu C, Yu H, Ren L Front Pharmacol. 2023; 14:1219362.

PMID: 37397499 PMC: 10311648. DOI: 10.3389/fphar.2023.1219362.

Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer.

Hargadon K Cell Mol Life Sci. 2023; 80(2):40.

PMID: 36629955 PMC: 11072992. DOI: 10.1007/s00018-023-04689-9.

Metabolism and Colorectal Cancer.

Sedlak J, Yilmaz O, Roper J Annu Rev Pathol. 2022; 18:467-492.

PMID: 36323004 PMC: 9877174. DOI: 10.1146/annurev-pathmechdis-031521-041113.

References

Koschny R, Walczak H, Ganten T . The promise of TRAIL--potential and risks of a novel anticancer therapy. J Mol Med (Berl). 2007; 85(9):923-35. DOI: 10.1007/s00109-007-0194-1. View

Geiss G, Bumgarner R, Birditt B, Dahl T, Dowidar N, Dunaway D . Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008; 26(3):317-25. DOI: 10.1038/nbt1385. View

Marshall C . Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995; 80(2):179-85. DOI: 10.1016/0092-8674(95)90401-8. View

Robinson G, Dinsdale D, MacFarlane M, Cain K . Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene. 2012; 31(48):4996-5006. DOI: 10.1038/onc.2012.13. View

Drosopoulos K, Roberts M, Cermak L, Sasazuki T, Shirasawa S, Andera L . Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem. 2005; 280(24):22856-67. DOI: 10.1074/jbc.M412483200. View

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

Turner A, Li L, Pilli T, Qian L, Wiley E, Setty S . MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS One. 2013; 8(2):e56817. PMC: 3574069. DOI: 10.1371/journal.pone.0056817. View

Meurette O, Fontaine A, Rebillard A, Le Moigne G, Lamy T, Lagadic-Gossmann D . Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann N Y Acad Sci. 2007; 1090:209-16. DOI: 10.1196/annals.1378.023. View

Raez L, Papadopoulos K, Ricart A, Chiorean E, DiPaola R, Stein M . A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012; 71(2):523-30. DOI: 10.1007/s00280-012-2045-1. View

10.

Soria J, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E . Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29(33):4442-51. DOI: 10.1200/JCO.2011.37.2623. View

11.

Yagita H, Takeda K, Hayakawa Y, Smyth M, Okumura K . TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004; 95(10):777-83. PMC: 11159975. DOI: 10.1111/j.1349-7006.2004.tb02181.x. View

12.

Renault F, Formstecher E, Callebaut I, Junier M, Chneiweiss H . The multifunctional protein PEA-15 is involved in the control of apoptosis and cell cycle in astrocytes. Biochem Pharmacol. 2003; 66(8):1581-8. DOI: 10.1016/s0006-2952(03)00514-8. View

13.

Zhang L, Fang B . Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2004; 12(3):228-37. DOI: 10.1038/sj.cgt.7700792. View

14.

Mulherkar N, Prasad K, Prabhakar B . MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells. J Biol Chem. 2007; 282(16):11715-21. DOI: 10.1074/jbc.M701085200. View

15.

Mohanti B, Rath G, Anantha N, Kannan V, Das B, Chandramouli B . Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys. 1996; 35(1):103-11. DOI: 10.1016/s0360-3016(96)85017-6. View

16.

Gambhir S . Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2(9):683-93. DOI: 10.1038/nrc882. View

17.

Landau B, Lubs H . Animal responses to 2-deoxy-D-glucose administration. Proc Soc Exp Biol Med. 1958; 99(1):124-7. DOI: 10.3181/00379727-99-24268. View

18.

Ashkenazi A . Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2(6):420-30. DOI: 10.1038/nrc821. View

19.

Singh D, Banerji A, Dwarakanath B, Tripathi R, Gupta J, Mathew T . Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol. 2005; 181(8):507-14. DOI: 10.1007/s00066-005-1320-z. View

20.

Smyth M, Takeda K, Hayakawa Y, Peschon J, van den Brink M, Yagita H . Nature's TRAIL--on a path to cancer immunotherapy. Immunity. 2003; 18(1):1-6. DOI: 10.1016/s1074-7613(02)00502-2. View